Vol. 6 No. 11 (2026): November
Reimbursement Reviews

Pembrolizumab (Keytruda)

decorative image of the issue cover

Published November 16, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Pembrolizumab (Keytruda), 100 mg per 4 mL vial, solution for IV infusion.
  • Indication: Pembrolizumab, in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with MIBC who are ineligible for cisplatin-containing chemotherapy.